TNFRSF9 and neoplasm: Prior studies have shown that utomilumab and urelumab, which are TNFRSF9 agonistic antibodies, can deliver costimulatory signals, enhancing T-cell–mediated anti-tumor activity in vitro and in vivo (reviewed in (Chester et al., 2018)).